Huaren Pharmaceutical: Subsidiary receives registration certificate for Compound Potassium Phosphate Hydrogen Injection, valid for 24 months.

Huaren Pharmaceutical announced that its wholly-owned subsidiary, Huaren Pharmaceutical Co., Ltd., recently received the Drug Registration Certificate for Compound Potassium Hydrogen Phosphate Injection approved and issued by the National Medical Products Administration. The drug approval number is Guoyaozhunzi H20266308, the drug is valid for 24 months, and the approval number is valid until October 19, 2031. The registration category is Class 3 chemical drugs, and upon approval it is deemed to have passed the consistency evaluation. In 2025, the total sales of Compound Potassium Hydrogen Phosphate Injection in the domestic medical market were 354 million yuan.